| 2001-10-01 |
Francis R. Cano, Ph.D. has served as a Director of the Company since June 1999. Dr. Cano currently works as a consultant in the biomedical field. |
| 2002-09-30 |
Francis R. Cano, Ph.D. has served as a Director of the Company since
June 1999. Dr. Cano currently works as a consultant in the biomedical field.
From 1996 to 1997, Dr. Cano served as Senior Vice President - Biotechnology of
BDM, an information technology company. From 1992 to 1996, he served as
President and Chief Operating Officer of Aviron, a public biotechnology company
focused on developing viral vaccines for disease prevention. Dr. Cano was also
involved in developing a vaccine business at a division of American Cynamid
Corporation. Dr. Cano also serves on the board of Lancer Orthodontics,Inc.
REPORT OF THE AUDIT COMMITTEE
The Audit Committee oversees the Company's financial reporting process
on behalf of the Board of Directors. Management has the primary responsibility
for the financial statements and the reporting process including the systems of
internal controls. In fulfilling its oversight responsibilities, the Committee
reviewed the audited financial statements in the Annual Report with management
including a discussion of the quality, not just the acceptability, of the
accounting principles, the reasonableness of significant judgments, and the
clarity of disclosures in the financial statements.
The Committee reviewed with the independent auditors, who are
responsible for expressing an opinion on the conformity of those audited
financial statements with generally accepted accounting principles, their
judgments as to the quality, not just the acceptability, of the Company's
accounting principles and such other matters as are required to be discussed
with the Committee has discussed with the independent auditors' the auditors'
independence from management and the Company including the matters in the
written disclosures required by the Independence Standards Board and considered
the compatibilty of non-audit services with the auditors' independence.
The Committee discussed with the Company's independent auditors the
overall scope and plans for their respective audit. The Committee meets with the
independent auditors, with and without management present, to discuss the
results of their examinations, their evaluations of the Company's internal
controls, and the overall quality of the Company's financial reporting. The
audit committee met once during the fiscal year ended May 31, 2002. |
| 2005-09-28 |
Francis R. Cano, Ph.D. 58 1999 Director |
| 2006-09-28 |
Francis R. Cano, Ph.D., 59, Director. Dr. Cano has served as a Director since June 1999. The Compensation Committee was comprised of Mr. Allen Barbieri and Dr. Francis Cano. The Audit Committee members are Mr. Barbieri and Dr. Cano. |
| 2007-09-28 |
Francis R. Cano, Ph.D., 60, Director. Compensation: $9,050 from stock option awards. |
| 2008-09-29 |
Francis R. Cano, Ph.D., 61, Director, member of Audit Committee, Member of Compensation Committee. Compensation: No direct payment, but granted options. Director compensation table shows $0 for fees and awards. |
| 2009-09-29 |
Francis R. Cano, Ph.D. 62 1999 Director, Member of Audit Committee, Member of Compensation Committee
The Audit Committee met one time during fiscal 2009. The members of the Audit Committee are Mr. Barbieri and Dr. Cano.
The Compensation Committee was comprised of Mr. Allen Barbieri and Dr. Francis Cano.
DIRECTOR COMPENSATION
Francis Cano, Ph.D. -0- -0- 4,901 -0- -0- -0- -0- -0- 4901 |
| 2010-09-29 |
Francis R. Cano, Ph.D., has served as a Director of the Company since June 1999. ... The Audit Committee met one time during fiscal 2010. The members of the Audit Committee are Mr. Barbieri and Dr. Cano. ... During fiscal 2010 the compensation committee was comprised of Mr. Allen Barbieri and Dr. Francis Cano. ... DIRECTOR COMPENSATION ... Francis Cano, Ph.D Option Awards ($) 3,677 Change in Pension Value and Nonqualified Deferred Compensation Earnings ($) -3,500 Total ($) 177 |
| 2011-09-28 |
Francis R. Cano, Ph.D., has served as a Director of the Company since June 1999. ... The Audit Committee met one time during fiscal 2011. The members of the Audit Committee are Mr. Barbieri and Dr. Cano. ... During fiscal 2011 the compensation committee was comprised of Mr. Allen Barbieri and Dr. Francis Cano. ... The following table presents the compensation of Non-Employee Directors for the fiscal year ended May 31, 2011. ... Francis Cano, Ph.D Fees Earned or Paid in Cash ($) -0- Option Awards ($) 7,672 Total ($) 7,672 |
| 2012-09-28 |
Francis R. Cano, Ph.D. 65 1999 Director, Member of Audit Committee,Member of Compensation Committee
... The following table presents the compensation of Non-Employee Directors for the fiscal year ended May 31, 2012.
Name Fees Earned or Paid in Cash ($) Stock Awards ($) Option Awards ($) Non-Equity Incentive Plan Compensation ($) Change in Pension Value and Nonqualified Deferred Compensation Earnings All Other Compensation ($) Total ($)
Francis Cano, Ph.D -0- -0- 6,661 -0- -0- -0- 6,661 |
| 2013-09-30 |
Francis R. Cano, Ph.D., has served as a Director of the Company since June 1999. ... The Audit Committee met one time during fiscal 2013. The members of the Audit Committee are Mr. Barbieri and Dr. Cano. ... During fiscal 2013, the Compensation Committee was comprised of Mr. Allen Barbieri and Dr. Francis Cano. ... The following table presents the compensation of Non-Employee Directors for the fiscal year ended May 31, 2013. ... Francis Cano, Ph.D Fees Earned or Paid in Cash ($) -0- Total ($) -0-. |
| 2014-09-29 |
Francis R. Cano, Ph.D., has served as a Director of the Company since June 1999. The Audit Committee met one time during fiscal 2014. The members of the Audit Committee are Mr. Barbieri and Dr. Cano. The Compensation Committee was comprised of Mr. Allen Barbieri and Dr. Francis Cano. |
| 2015-09-28 |
Francis R. Cano, Ph.D., 68, Director, Member of Audit Committee and Member of Compensation Committee. Director compensation: $24,599 in 2015. |
| 2016-09-28 |
Francis R. Cano, Ph.D. 69 1999 Director, Member of Audit Committee, Compensation Committee and Nominating Committee ... The following table presents the compensation of Non-Employee Directors for the fiscal year ended May 31, 2016 ... Francis Cano, Ph.D Fees Earned or Paid in Cash ($) -0- Option Awards ($) 21,315 Total ($) 21,315 |
| 2017-09-28 |
Francis R. Cano, Ph.D., 70, Director, Member of Compensation Committee and Chairman of Nominating and Corporate Governance Committee. No cash compensation; no compensation reported for 2017. |
| 2018-09-28 |
Francis R. Cano, Ph.D., 74, Director, Member of Compensation Committee and Chairman of Nominating and Corporate Governance Committee. Total compensation for fiscal 2018 was $50,293. |
| 2019-09-24 |
The following table sets forth the name and current age of each nominee for director, the year he or she was first elected a director and his or her position(s) with the Company. The Company does not pay a fee to any third party to identify potential nominees. The Board has not received recommended nominees from a stockholder. | Name | Age | Director Since | Positions Held | | Francis R. Cano, Ph.D. | 75 | 1999 | Director, Member of Compensation Committee and Chairman of Nominating and Corporate Governance Committee | ... Although not prohibited by the Company's Bylaws, directors receive no cash compensation for their services as directors, but they have been, and may in the future be, granted options to purchase the Company's securities which serves as compensation for their services. The compensation of directors is subject to review and adjustment from time to time by the Board of Directors. The following table presents the compensation of Non-Employee Directors for the fiscal year ended May 31, 2019. - 10 - DIRECTOR COMPENSATION Although not prohibited by the Company's Bylaws, directors receive no cash compensation for their services as directors, but they have been, and may in the future be, granted options to purchase the Company's securities which serves as compensation for their services. The compensation of directors is subject to review and adjustment from time to time by the Board of Directors. The following table presents the compensation of Non-Employee Directors for the fiscal year ended May 31, 2019. - 10 - DIRECTOR COMPENSATION | Name | Fees Earned or Paid in Cash ($) | Stock Awards ($) | Option Awards ($) | Non-Equity Incentive Plan Compensation ($) | Change in Pension Value and Nonqualified Deferred Compensation Earnings | All Other Compensation ($) | Total ($) | | Allen Barbieri | -0- | -0- | 61,100 | -0- | -0- | -0- | -0- | 61,100 | | Francis Cano, Ph.D | -0- | -0- | 42,770 | -0- | -0- | -0- | 42,770 | ... (1) All outside directors each received a 35,000 share stock option grant in fiscal 2019 except for Allen Barbieri, who received a 50,000 share stock option grant. The options were granted at the exercise price of $2.25 per share (market value on the date of grant). The grants for 35,000 were valued at $42,770 and the option for 50,000 was valued at $61,100 using the Black-Scholes options-pricing model (which uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term and the risk-free interest rate).
| 2020-09-25 |
Francis R. Cano, Ph.D., 76, Director, Member of Compensation Committee and Chairman of Nominating and Corporate Governance Committee. Compensation: $46,020 in fiscal 2020. |
Celldex Therapeutics, Inc.
| Filing Date |
Source Excerpt |
| 2006-04-19 |
Dr. Cano is currently President of Cano Biotechnology Corporation. In 1996, he started the Cano Biotechnology Corporation, where he consults with vaccine leaders, small private and public biotechnology companies, venture groups, and universities. Dr. Cano formerly served as Chairman and Chief Executive Officer of Vaxin Inc. from 2003 to 2005 and as a director from 2001 to 2005. |
| 2007-04-20 |
Dr. Cano is currently President of Cano Biotechnology Corporation which he founded in 1996. The company focuses on vaccines, advising major vaccine and biotechnology companies, venture companies, and universities. |
|